TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05194449

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comfort Talk® App
Description: Patients will receive a tablet preloaded with the Comfort Talk® app in the dental waiting room on an intent-to-treat basis. They can listen as much or as little as they wish during waiting and during their dental treatment. Upon departure, they will receive a download coupon for the app for home use.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo App
Description: Patients will receive a tablet preloaded with a white noise app in the dental waiting room on an intent-to-treat basis. They can listen as much or as little as they wish during waiting and during their dental treatment.
Study: NCT06716307

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CagriSema (cagrilintide B and semaglutide I)
Description: Cagrilintide and semaglutide will be administered subcutaneously using DV3384 pen-injector.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CagriSema (cagrilintide B and semaglutide I)
Description: Cagrilintide and semaglutide will be administered subcutaneously using DV3384 pen-injector.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CagriSema A
Description: Cagrilintide and semaglutide will be administered subcutaneously using PDS290 pen-injector.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CagriSema A
Description: Cagrilintide and semaglutide will be administered subcutaneously using PDS290 pen-injector.
Study: NCT06731556

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous paracetamol
Description: Paracetamol was administered intravenously at a dose of 20 mg/kg/day, twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Paracetamol
Description: Paracetamol at a concentration of 1.25 mg/mL was administered intranasally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Diclofenac Sodium
Description: Diclofenac sodium at a concentration of 0.0625 mg/mL was administered intranasally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Ibuprofen
Description: Ibuprofen at a concentration of 0.375 mg/mL was administered intranasally.
Study: NCT06736548

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Sleep Treatment Education Program Together (STEP-Together)
Description: STEP-Together is delivered in a single videoconference group session delivered live by a presenter. During the session, the participants are able to see and hear the presenter, view the presentation slides, and ask questions. The presentation includes educational information on the problem of insomnia after cancer and specific suggestions for improving sleep. Suggestions are presented in four sections addressing lifestyle issues, sleep environment, sleep timing, and managing expectations and challenges. During the course of the session, participants are asked to use these suggestions to develop an individual sleep action plan they will use to improve their sleep.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coaching Session
Description: Coaching sessions are brief (\<1hour) sessions intended to support participants in implementing their personal sleep self-management plan. In the session, participants are asked to review their progress with their plan, report on areas of sucess and difficulty with adoption, and to problem solve with the study team as needed to support their sucessful implementation their plan.
Study: NCT06759311

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ART
Description: The restorative procedure performed in relative isolation and without the use of anesthesia consisted of removal of the carious tissue using hand instrument excavators and dentin

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brix 3000
Description: Brix 3000 gel will be applied to the caries lesion using a spoon excavator\*\* leaving gel according to the manufacturer's instructions. After 2 minutes, the gel will turn from translucent green colour to cloudy after the gel removal.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carie Move
Description: Carie-Move gel will be applied to the caries lesion according to the manufacturer's instructions at second visit in the same child. After 30 second the gel will be removed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smart Bur
Description: Removal of carious dentin will be carried out employing smart bur II mounted on a low-speed handpiece without water spray. Caries removal will be proceeded until the smart bur II becomes dull after repeated contact with healthy dentin (21) (figure 3)
Study: NCT05557955

Intervention type: OTHER
Intervention: Breathing test
Description: Dynamic breathing testing will be performed before, during, and after radiotherapy. Volatile organic compounds (VOCs) will be collected.

Intervention type: OTHER
Intervention: Breathing test
Description: Dynamic breathing testing will be performed before, during, and after radiotherapy. Volatile organic compounds (VOCs) will be collected.
Study: NCT06760091

Intervention type: OTHER
Intervention: baseline data collection and follow-up
Description: At the time of enrollment, baseline characteristics will be collected, and each subject will be followed up for 2 years through face-to-face, telephone, or online visits. During the follow-up period, the clinical prognosis will be recorded.
Study: NCT06759233

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endoscopic cryoballoon ablation treatment(ECAT)+PD-1
Description: ECAT: A cryoballoon with catheter is inserted along the endoscopic forceps channel, the balloon is placed on the surface of the tumor, and the balloon is dilated so that it fits snugly over the lesion. The freezing cycle is initiated and continued for 2-3 minutes, and then the balloon is rewarmed and frozen again for 2-3 minutes; the freeze-rewarm cycle is repeated twice.~PD-1:The first PD-1 monoclonal antibody treatment in this study was given within 3 days before and after ECAT treatment, and subsequent treatment was given every three weeks according to the instructions.
Study: NCT06758674

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: education
Description: Prepared in clear language and supported with visuals in line with guidelines and studies (Kottner et al. 2019, Orhan 2017, APUPA 2011, EPUAP and NPUAP 2009, EPUAP 2019, Arıkan and vanGiersbergen 2019, Arslantaş et al. 2018) training will be given to prevent pressure ulcers. Training content will be sent to expert opinion for content validity. In the content of the training, the definition of pressure ulcers, how they develop, high-risk areas for wound formation, identification of risks, evaluation of the skin, skin care, lying positions and position changes, supporting bone protrusions with pillows, lying on a support surface, nutritional status and content, fluid intake will be discussed.
Study: NCT06760117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan (CPT-11)
Description: Irinotecan will start at a dose of 50mg/m² and escalate to explore the maximum tolerated dose.

Intervention type: DRUG
Group type: OTHER
Intervention: Irinotecan (CPT-11)
Description: Irinotecan will start at a dose of 50mg/m² and escalate to explore the maximum tolerated dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide (TMZ)
Description: TMZ：100mg/m2/d，d1-5

Intervention type: DRUG
Group type: OTHER
Intervention: Temozolomide (TMZ)
Description: TMZ：100mg/m2/d，d1-5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: VCR: 1.5mg/m2/d(≯2mg), d1

Intervention type: DRUG
Group type: OTHER
Intervention: Vincristine
Description: VCR: 1.5mg/m2/d(≯2mg), d1
Study: NCT06759857

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FHND9041
Description: FHND9041 is a novel therapeutic agent targeting EGFR mutations. Participants will take an 80 mg oral dose once daily until disease progression, intolerable toxicity, or meeting other study-defined discontinuation criteria.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Afatinib
Description: Afatinib is an approved, second-generation, irreversible EGFR tyrosine kinase inhibitor used as a standard first-line treatment for non-small cell lung cancer (NSCLC) with EGFR-sensitive mutations, such as L858R and Exon 19 deletions. Participants in this arm will take a 40 mg oral dose once daily. Afatinib serves as the active comparator in this study to evaluate the efficacy and safety of FHND9041.
Study: NCT06758726

Intervention type: DRUG
Group type: OTHER
Intervention: Mitoxantrone Hydrochloride Liposome combined with BU/Cy
Description: Mitoxantrone hydrochloride liposome (30 mg/m\^2) on day -9, iv Busulfan (3.2mg/kg/d) on day -7\~-5, iv Cyclophosphamide (60 mg/kg/d) on day -3\~-2, iv
Study: NCT06760013

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Su Jok Therapy
Description: The researcher, who has a Su-Jok practitioner certificate, applied pressure for 1-2 minutes on the active point on the meridian (the area between the 3rd and 4th fingers pointing to the uterus) that provides energy flow in the palm in 20-minute periods, with the help of a diagnostic probe (diagnostic stick). The point will be determined. Once this point is detected, a massage will be performed on the point. The massage will be applied with a 10-minute rest period between each two periods.
Study: NCT06758713

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR-T
Description: CAR T-cell therapy involves autologous chimeric antigen receptor T-cells, capable of targeting human B cell maturation antigen (BCMA) ,CD19 or CD-7 etc. target molecules of other hematologic malignancies.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR-T
Description: CAR T-cell therapy involves autologous chimeric antigen receptor T-cells, capable of targeting human B cell maturation antigen (BCMA) ,CD19 or CD-7 etc. target molecules of other hematologic malignancies.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR-T
Description: CAR T-cell therapy involves autologous chimeric antigen receptor T-cells, capable of targeting human B cell maturation antigen (BCMA) ,CD19 or CD-7 etc. target molecules of other hematologic malignancies.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR-T
Description: CAR T-cell therapy involves autologous chimeric antigen receptor T-cells, capable of targeting human B cell maturation antigen (BCMA) ,CD19 or CD-7 etc. target molecules of other hematologic malignancies.
Study: NCT05184946

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab Combined with SOX
Description: Administer camrelizumab and SOX regimen in the adjuvant treatment of advanced gastric adenocarcinoma or gastric esophageal junction adenocarcinoma
Study: NCT06193005

Intervention type: OTHER
Intervention: no intervention
Description: no intervention

Intervention type: OTHER
Intervention: no intervention
Description: no intervention

Intervention type: OTHER
Intervention: no intervention
Description: no intervention

Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study: NCT04783246

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Fitness
Description: The group fitness intervention will involve streaming a group fitness class lead by a certified personal trainer. certified personal trainer and include variations of body-weight strength and aerobic exercise activities. Each work out session will be 30 minutes in duration and follow a structure of a warm-up period, alternating strength and aerobic exercises of varying intensity, and a cool-down period. The videos will be streamed to the group by a facilitator over Zoom video conferencing.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group Fitness
Description: The group fitness intervention will involve streaming a group fitness class lead by a certified personal trainer. certified personal trainer and include variations of body-weight strength and aerobic exercise activities. Each work out session will be 30 minutes in duration and follow a structure of a warm-up period, alternating strength and aerobic exercises of varying intensity, and a cool-down period. The videos will be streamed to the group by a facilitator over Zoom video conferencing.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutrition education
Description: The nutrition education intervention will involve 45-minute educational sessions involving didactic teaching, interactive goal setting, and a live cooking demonstration. Each session will be taught by a registered dietician who will also be responsible for designing the curriculum schedule.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition education
Description: The nutrition education intervention will involve 45-minute educational sessions involving didactic teaching, interactive goal setting, and a live cooking demonstration. Each session will be taught by a registered dietician who will also be responsible for designing the curriculum schedule.
Study: NCT02734719

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bonestim
Description: Bonestim is the multipad electrical stimulation device.
Study: NCT05279989

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Seated Tai Chi Qigong
Description: Participants will receive seated Tai Chi Qigong videos.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Health Information Videos
Description: Participants will receive videos of health information.
Study: NCT04767633

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: split dose vs standard dose of sodium pico sulfate plus magnesium sulfate in children for bowel cleansing
Description: The preparations will be dispensed by a nurse who carefully explained how the products should be taken, emphasising the importance of complete intake of the solution to ensure a safe and effective procedure. Moreover, each patient will be provided with dietary instructions: low residue diet for 3 days before colonoscopy. During and after bowel preparation, solid food will not be allowed. Clear liquid could be taken until 2 hours before the procedure. All colonoscopy will be performed between 11:00 and 15:00 by two endoscopists.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: split dose vs standard dose of sodium pico sulfate plus magnesium sulfate in children for bowel cleansing
Description: The preparations will be dispensed by a nurse who carefully explained how the products should be taken, emphasising the importance of complete intake of the solution to ensure a safe and effective procedure. Moreover, each patient will be provided with dietary instructions: low residue diet for 3 days before colonoscopy. During and after bowel preparation, solid food will not be allowed. Clear liquid could be taken until 2 hours before the procedure. All colonoscopy will be performed between 11:00 and 15:00 by two endoscopists.
Study: NCT05590468

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nicotinamide Riboside
Description: Vitamin B3 derivative; a total of 1000 mg/day in a regimen of 500mg every 12 hours by mouth (either fasting or fed)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Looks exactly like the study drug, but it contains no active ingredient
Study: NCT06075212

Intervention type: DRUG
Intervention: blinatumomab
Description: The dose of one course was as follows: day 1-2: 8ug/day, continuous intravenous drip for 24 hours, day 3-7: 16ug/day, continuous intravenous drip for 24 hours. Treatment with blinatumomab was initiated within 60 to 90 days after transplantation and was administered bimonthly until 1 year after transplantation. Dexamethasone 20mg was administered 1 hour before administration on days 1 and 3 to prevent adverse events.

Intervention type: DRUG
Intervention: blinatumomab
Description: The dose of one course was as follows: day 1-2: 8ug/day, continuous intravenous drip for 24 hours, day 3-7: 16ug/day, continuous intravenous drip for 24 hours. Treatment with blinatumomab was initiated within 60 to 90 days after transplantation and was administered bimonthly until 1 year after transplantation. Dexamethasone 20mg was administered 1 hour before administration on days 1 and 3 to prevent adverse events.
Study: NCT03394976

Intervention type: DIAGNOSTIC_TEST
Intervention: No intervention
Description: No intervention
Study: NCT06323902

Intervention type: PROCEDURE
Intervention: Pars plana vitrectomy, with or without epiretinal membrane peeling, plus PRGF membrane implantation
Description: In the operating room through pars plana vitrectomy after having completed the complete air exchange, with the help of a Backwash Charles cannula, the PRGF membrane is placed in the macular hole and C3F8 gas is left in the posterior chamber, the first hour in the recumbent position. supine and subsequently face down during the first postoperative week.
Study: NCT05732701

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Algorithm-guided DAPT duration
Description: PRECISE-DAPT score ≥25~* Chronic Coronary Syndromes (CCS): Aspirin + clopidogrel for 1 month, followed by clopidogrel monotherapy~* Acute Coronary Syndromes (ACS): Aspirin + ticagrelor for 1 month, followed by ticagrelor monotherapy~PRECISE-DAPT score \<25:~* Non-complex CCS: Aspirin + clopidogrel for 6 months, followed by clopidogrel monotherapy~* Non-complex ACS: Aspirin + potent P2Y12 inhibitor for 6 months, followed by potent P2Y12 inhibitor monotherapy~* Complex CCS or ACS: Aspirin + P2Y12 inhibitor for 12 months, followed by P2Y12 inhibitor monotherapy (potent P2Y12 inhibitor mandatory for ACS)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard-of-care DAPT duration
Description: DAPT strategy at the operators´ discretion in accordance with applicable guidelines
Study: NCT06225427

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tissue biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo echocardiography
Study: NCT06760403

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hypochlorous acid
Description: Hypochlorous acid, chlorhexidine and saline groups were compared as postoperative gargles after gingivectomy surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypochlorous acid
Description: Hypochlorous acid, chlorhexidine and saline groups were compared as postoperative gargles after gingivectomy surgery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hypochlorous acid
Description: Hypochlorous acid, chlorhexidine and saline groups were compared as postoperative gargles after gingivectomy surgery.
Study: NCT06760377

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary supplement Group
Description: Subjects belonging to the experimental group will be provided with the PermeaIntest supplement, which they will take for 60 days, 1 sachet in the morning and 1 sachet in the evening in half a glass of water. Subjects will have a stool sample collected before and after ingestion of the dietary supplement.
Study: NCT06759896

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Protraction facemask
Description: Patients assigned to intervention 1 will utilize the Petit protraction facemask, in conjunction with a rapid maxillary expansion (RME). This facemask consists of a forehead pad and chin pad linked by a sturdy steel support rod.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Upper partial fixed appliance
Description: Upper partial fixed appliance / 2 by 4 appliance will be used in this study by using bracket set (119-142 Unitek™ Gemini Bracket MBT™ U/L 5x5 0T-Cuspid 3Hk) with molar bands (3M™ Victory Series™ First Molar Bands) or buccal tubes (3M™ Victory Series™ Superior Fit Buccal Tubes) and upper nickel titanium archwires (3M™ Unitek™ Nitinol Heat-activated Archwire) and upper stainless steel archwires (3M™ Unitek™ Permachrome Standard Archwire) .
Study: NCT06758661

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D352
Description: 1 tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D352
Description: 1 tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D794
Description: 4 capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D794
Description: 4 capsule
Study: NCT06758804

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Winterized Pistacia Lentiscus Oil Nasal Drops (Bactorinol®)
Description: Participants will receive winterized Pistacia lentiscus oil nasal drops (Bactorinol®), administered as 3 drops per nostril, three times daily for six consecutive days.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Saline Solution (0.9% NaCl)
Description: Participants will receive a saline solution (0.9% NaCl) administered as 3 drops per nostril, three times daily for six consecutive days.
Study: NCT06347432

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Power wheelchair skills training using the IndieTrainer system
Description: The IndieTrainer system will be used to provide the power wheelchair (PWC) skills training sessions. The IndieTrainer is comprised of a mobility device and an array of video-based gamified training modules designed to facilitate PWC training. The IndieTrainer mobility device temporarily converts a manual wheelchair into a powered wheelchair, thereby allowing children to remain in their own manual wheelchair and use their own custom seating system during power wheelchair skills training activities. Principles outlined in the Assessment of Learning Powered mobility use (ALP) Facilitating Strategies for each ALP Assessment phase will guide the intervention sessions.
Study: NCT05783661

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional antibiotic strategies
Description: Treatment according to the local guidelines of the Hospital Clinic de Barcelona.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Regimens guided by epidemiological surveillance
Description: Treatment according to the local guidelines of the Hospital Clinic de Barcelona guided by colonization/epidemiological surveillance.
Study: NCT05273463

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video-Based Intervention
Description: 15-minute video about what to expect before, during, and after your surgery
Study: NCT06225427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gilteritinib
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT04287114

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acute exercise
Description: Acute exercise with different exercise intensities